BioCentury | Sep 12, 2016
Clinical News

Annexin V-128: Phase II started

...Advanced Accelerator began an open-label, Canadian Phase II trial to evaluate 99mTc-rhAnnexin V-128 followed by carotid ultrasound...
...within 2 years. Advanced Accelerator Applications S.A. (NASDAQ:AAAP), Saint Genis Pouilly, France Product: Annexin V-128 ( 99mTc-rhAnnexin V-128...
BioCentury | Sep 12, 2016
Clinical News

Annexin V-128: Phase II started

...Advanced Accelerator began an open-label, Canadian Phase II trial to evaluate 99mTc-rhAnnexin V-128 followed by cardiac MRI...
...receiving doxorubicin-based chemotherapy. Advanced Accelerator Applications S.A. (NASDAQ:AAAP), Saint Genis Pouilly, France Product: Annexin V-128 ( 99mTc-rhAnnexin V-128...
BioCentury | Jan 19, 2015
Clinical News

99mTc-rhAnnexin V-128: Phase I/IIa started

...Advanced Accelerator Applications began an open-label Phase I/IIa trial to evaluate 0.4 mg IV 99mTc-rhAnnexin V-128 given...
...from an undisclosed third party. Advanced Accelerator Applications S.A. , Saint Genis Pouilly, France Product: 99mTc-rhAnnexin V-128...
BioCentury | Jan 19, 2015
Company News

Atreus Pharmaceuticals, Advanced Accelerator Applications deal

...own and renamed the fully owned subsidiary to AAA Canada. Through the acquisition, AAA gains 99mTc-rhAnnexin V-128...
...RA) and ankylosing spondylitis (AS) and monitor drug treatment. The new subsidiary will also evaluate 99mTc-rhAnnexin V-128...
Items per page:
1 - 4 of 4